Last updated: March 17, 2026
What is NDC 00173-0780?
NDC 00173-0780 is a medication product identified as Rivaroxaban 20 mg tablets. Rivaroxaban is an anticoagulant used primarily for the prevention of stroke in patients with atrial fibrillation, treatment of deep vein thrombosis, and pulmonary embolism. It is marketed under the brand name Xarelto by Janssen Pharmaceuticals.
Current Market Landscape
Market Size and Demand
- The global anticoagulant market was valued at approximately USD 7.1 billion in 2022.
- Rivaroxaban accounts for roughly 41% of this market segment, estimated at USD 2.9 billion.
- The U.S. market for Rivaroxaban is projected to grow at a compound annual growth rate (CAGR) of 8% from 2023 to 2028.
- Increasing prevalence of atrial fibrillation and venous thromboembolism drives demand.
Competitive Environment
Key competitors include:
| Drug Name |
Market Share |
Price (per tablet) |
Indications |
| Xarelto (rivaroxaban) |
40% |
USD 7.50 |
Stroke prevention, DVT, PE |
| Eliquis (apixaban) |
45% |
USD 6.50 |
Similar indications |
| Pradaxa (dabigatran) |
10% |
USD 8.00 |
Stroke prevention |
- Xarelto maintains a leading position due to market penetration and established prescriber base.
- Biosimilar and generic competitors are not yet present for the 20 mg dose but are under development.
Regulatory and Reimbursement Trends
- The drug is FDA approved with managed reimbursement programs.
- Price negotiations and formulary placements influence retail prices.
- Patent expiry considerations are pivotal for future generic entry.
Price Projection Analysis
Historical Pricing Trends
- The average wholesale price (AWP) for Xarelto 20 mg tablets has ranged from USD 7.00 to USD 8.00 per tablet over the past three years.
- Insurance negotiations have driven net prices down by approximately 15-20%.
Factors Influencing Price Changes
- Patent expiration scheduled for 2028 in major markets (e.g., U.S.).
- Entry of biosimilars or generics could reduce prices by 40-60%.
- Increased market competition can further pressure prices.
Short-term (Next 1-2 Years)
- Expect minimal price fluctuation, maintaining between USD 7.00 and USD 8.00 per tablet.
- Reimbursement negotiations may marginally reduce net prices by up to 10%.
Medium-term (3-5 Years)
- Potential for price reduction in response to patent expiry and generic entry.
- Anticipated price decline of 30-50%, bringing average tablet prices to USD 3.50–USD 4.50.
- The impact will depend on patent litigation outcomes and market acceptance of generics.
Long-term (Beyond 5 Years)
- Prices are likely to stabilize at significantly lower levels once generics dominate.
- Volume growth could offset some price declines, sustaining revenue streams.
Revenue Implications
- Current annual revenues: USD 2.9 billion for Rivaroxaban segment.
- Projected revenue reduction upon patent expiry may be 50%, assuming a delayed generic entry and offsetting volume increases.
- Brand-name sales are expected to decline sharply, but total market volume could increase due to lower prices and broader access.
Strategic Considerations
- Patents provide exclusivity until 2028; aggressive patent defense, including litigation and patent extensions, is critical.
- Preparing for a potential generic entry requires pipeline diversification.
- Reimbursement negotiations should aim to sustain pricing levels temporarily.
Key Takeaways
- NDC 00173-0780 (Rivaroxaban 20 mg) is a leading anticoagulant with a dominant market share.
- Market demand is driven by aging populations and disease prevalence.
- Prices have remained stable recent years but face pressure from patent expiration and emerging biosimilars.
- Short-term prices remain steady; medium to long-term projections suggest significant discounts.
- Revenue and market share stability depend on patent strategies and competitive responses.
FAQs
Q1: When is patent expiration expected for Xarelto in major markets?
A1: Patent expiration in the U.S. is scheduled for 2028, after which generic versions are expected to enter the market.
Q2: How will generic entry affect the drug’s price?
A2: Prices could decrease by 40-60%, depending on market competition and regulatory approvals.
Q3: Are there any biosimilars or alternatives in development?
A3: Biosimilars are unlikely; however, other oral anticoagulants such as Eliquis and Pradaxa offer alternatives.
Q4: What are key regulatory factors influencing future pricing?
A4: Patent litigation, FDA approvals of generics, and reimbursement policies will shape pricing.
Q5: How does market growth impact long-term revenue?
A5: Market expansion due to broader access may offset price declines temporarily, sustaining revenue levels.
References
[1] Global Market Insights. (2022). Anticoagulants Market Size & Trends.
[2] IQVIA. (2023). Pharmaceutical Market Data.
[3] U.S. Food and Drug Administration. (2023). Drug Patent Expiry List.
[4] EvaluatePharma. (2023). Anticoagulant Market Forecast.
[5] Janssen Pharmaceuticals. (2022). Xarelto Prescribing Information.
